Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T16:28:20.497Z.
Calculation as of: 2026-10-06T16:28:20.497Z.
Quote observation: 2026-10-06T16:23:46.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$105.67M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$102.56M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$103.07M
Free Cash Flow Yield
4.10%
TTM Avg
1.81%
3Y Avg
3.57%
5Y Avg
3.20%
Market Cap
$103.09M
Free Cash Flow Yield
N/A
TTM Avg
6.54%
3Y Avg
6.54%
5Y Avg
6.54%
Market Cap
$105.47M
Free Cash Flow Yield
27.08%
TTM Avg
25.60%
3Y Avg
13.86%
5Y Avg
9.06%
Market Cap
$107.83M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.23M
Free Cash Flow Yield
N/A
TTM Avg
10.25%
3Y Avg
16.93%
5Y Avg
15.95%
Market Cap
$97.80M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $105.67M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $102.56M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $103.07M | 4.10% | 1.81% | 3.57% | 3.20% |
| Anixa Biosciences, Inc. (ANIX)vs › | $103.09M | N/A | 6.54% | 6.54% | 6.54% |
| Definitive Healthcare Corp. (DH)vs › | $105.47M | 27.08% | 25.60% | 13.86% | 9.06% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.83M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | N/A | 10.25% | 16.93% | 15.95% |
| Conexeu Sciences Inc. (CNXU)vs › | $97.80M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $108.15M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.59M | N/A | 13.79% | 13.79% | 13.79% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
